Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A medical consultation is requested for an inpatient who was admitted earlier today for severe confusion and generalized weakness. The patient was recently diagnosed with a right hilar mass, and a subsequent biopsy confirmed squamous cell carcinoma of the lung. Clinical evaluation reveals profound lethargy, decreased skin turgor, and dry oral mucous membranes.

Laboratory studies demonstrate:
Serum calcium: 14.614.6 mg/dL
Serum phosphorus: 2.12.1 mg/dL
Blood urea nitrogen: 6868 mg/dL
Serum creatinine: 3.23.2 mg/dL (baseline 0.90.9 mg/dL two weeks ago)
Intact parathyroid hormone (PTH): 88 pg/mL (normal: 10−6510-65 pg/mL)

Aggressive volume resuscitation with intravenous isotonic saline and administration of calcitonin have been initiated. Which of the following is the most appropriate next step in this patient's pharmacologic management?

  1. Subcutaneous denosumabAnswer
  2. B
    Intravenous zoledronic acid
  3. C
    Intravenous furosemide
  4. D
    Intravenous hydrocortisone
  5. E
    Oral cinacalcet

Answer

The correct answer is subcutaneous denosumab.
Denosumab is a monoclonal antibody that targets the receptor activator of nuclear factor kappa-B ligand (RANKL), effectively halting osteoclast-mediated bone resorption. While intravenous bisphosphonates (e.g., zoledronic acid, pamidronate) are typically the first-line definitive treatment for hypercalcemia of malignancy following initial fluid resuscitation, they are nephrotoxic and contraindicated in patients with severe renal impairment or acute kidney injury. Denosumab undergoes reticuloendothelial clearance rather than renal clearance, making it the guideline-concordant pharmacologic intervention of choice for this patient's hypercalcemia in the setting of a significantly elevated creatinine.

Step-by-Step Solution

1
Identify the etiology and severity of the metabolic derangement.
The patient has severe hypercalcemia of malignancy (calcium > 14.014.0 mg/dL) driven by parathyroid hormone-related peptide (PTHrP) from a squamous cell lung carcinoma, leading to suppressed intact PTH.
Establishing the specific mechanism of hypercalcemia directs the choice of targeted pharmacotherapy.
2
Assess the patient's end-organ function and volume status based on laboratory findings.
The patient has profound volume depletion (BUN/Cr ratio > 2020) and acute kidney injury (creatinine elevated to 3.23.2 mg/dL from baseline).
Renal function directly dictates the safety profile of calcium-lowering agents.
3
Select the appropriate definitive calcium-lowering therapy that is safe for the patient's clinical profile.
Denosumab is chosen over intravenous bisphosphonates.
Standard IV bisphosphonates are highly nephrotoxic and contraindicated in acute kidney injury. Denosumab, a monoclonal antibody, is cleared via the reticuloendothelial system and is safe in severe renal impairment.

Key Concept

In patients with severe hypercalcemia of malignancy and concurrent acute kidney injury or severe renal impairment, denosumab is the preferred definitive calcium-lowering agent because intravenous bisphosphonates are contraindicated due to nephrotoxicity.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic